H. Karmouty-Quintana (Houston, United States of America), H. Olschewski (Graz, Austria), L. Price (London, United Kingdom), S. Bonnet (Québec (QC), Canada)
Inhaled liposomal iloprost extend detectable plasma level and prolong reduction of hypoxia-induced pulmonary hypertension in rat
P. Kan (Taipei, Taiwan), K. Chen (Taipei, Taiwan), Y. Lin (Taipei, Taiwan)
|  |
Pulmonary vascular cell mitochondrial dysfunction in response to hepcidin
T. Issitt (London, United Kingdom), Q. Toe (London, United Kingdom), M. Mohd Ghazaly (London, United Kingdom), G. Quinlan (London, United Kingdom), S. Wort (London, United Kingdom)
| |
Targeting of mitochondrial superoxide in chronic hypoxia-induced pulmonary hypertension
N. Alebrahimdehkordi (Giessen, Germany), O. Pak (Giessen, Germany), S. Scheibe (Giessen, Germany), M. Gierhardt (Giessen, Germany), A. Sydykov (Giessen, Germany), M. Hecker (Giessen, Germany), K. Schaefer (Giessen, Germany), W. Seeger (Giessen, Germany), H. Ghofrani (Giessen, Germany), R. Schermuly (Giessen, Germany), M. Murphy (Cambridge, United Kingdom), N. Weissmann (Giessen, Germany), N. Sommer (Giessen, Germany)
| |
Pharmacological inhibition of carbonic anhydrases 9 and 12 attenuates monocrotaline-induced pulmonary hypertension in rats
A. Petrovic (Giessen, Germany), D. Kosanovic (Giessen, Germany), O. Pak (Giessen, Germany), J. Schneider (Giessen, Germany), A. Sydykov (Giessen, Germany), N. Weissmann (Giessen, Germany), W. Seeger (Giessen, Germany), R. Schermuly (Giessen, Germany)
| |
Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension
E. Schiavi (Parma, Italy), S. Cantoni (Parma, Italy), G. Volpi (Parma, Italy), M. Cont (Parma, Italy), F. Pastore (Parma, Italy), S. Cavalli (Parma, Italy), F. Dardi (Bologna, Italy), G. Villetti (Parma, Italy), F. Facchinetti (Parma, Italy)
| |
Activation of de novo NAD synthesis in the lung of pulmonary hypertension
Z. Cai (Rotterdam, Netherlands), C. Van Der Ley (Groningen, Netherlands), M. Van Faassen (Groningen, Netherlands), I. Kema (Groningen, Netherlands), D. Duncker (Rotterdam, Netherlands), D. Merkus (Rotterdam, Netherlands)
|  |
Sex and age differences in pulmonary vascular responses in a chronic hypoxic rat model
E. Olea (Valladolid, Spain), J. Prieto-Lloret (Valladolid, Spain), A. Gordillo (Valladolid, Spain), A. Gomez-Niño (Valladolid, Spain), A. Obeso (Valladolid, Spain), R. Rigual (Valladolid, Spain), A. Rocher (Valladolid, Spain)
| |
RF22c, a 5-lipoxygenase inhibitor, in monocrotaline-induced PAH
A. Liparulo (Naples, Italy), R. Esposito (Naples, Italy), S. Mirra (Naples, Italy), G. Spaziano (Naples, Italy), A. Muñoz Ramírez (Santiago de Chile, Chile), A. Capuano (Naples, Italy), R. Filosa (Naples, Italy), C. Puglia (Catania, Italy), B. D'Agostino (Naples, Italy)
| |
In-vivo lung molecular imaging of choline metabolism in a rat model of pulmonary arterial hypertension
J. Izquierdo-Garcia (Donostia, Spain), L. Fadon (Donostia, Spain), M. Beraza (Donostia, Spain), U. Cossio (Donostia, Spain), J. Llop (Donostia, Spain), J. Ruiz-Cabello (Donostia, Spain)
| |
Role of vasoactive mediators on cigarette smoke extract (CSE)-induced proliferation in human pulmonary artery smooth muscle cells (hPASMCs)
A. Alqarni (Nottingham, United Kingdom), O. Brand (Nottingham, United Kingdom), A. Pasini (Nottingham, United Kingdom), A. Alghamdi (Nottingham, United Kingdom), W. Alshehri (Nottingham, United Kingdom), M. Alahmari (Nottingham, United Kingdom), L. Pang (Nottingham, United Kingdom)
| |
Role of IL-11 in vascular function of pulmonary fibrosis patients
I. Roger (Valencia, Spain), C. Estornut (Valencia, Spain), B. Ballester (Valencia, Spain), J. Milara (Valencia, Spain), J. Cortijo (Valencia, Spain)
| |
Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH).
V. Gaynitdinova (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), G. Necludova (Moscow, Russian Federation), G. Nuralieva (Moscow, Russian Federation), N. Trushenko (Moscow, Russian Federation)
| |
Survival implications of pulmonary hypertension in end-stage COPD
A. Kapasi (Edmonton, Canada), K. Halloran (Edmonton, Canada), A. Hirji (Edmonton, Canada), D. Lien (Edmonton, Canada), J. Mooney (Palo Alto, United States of America), R. Raj (Palo Alto, United States of America), A. Sweatt (Palo Alto, United States of America), J. Weinkauf (Edmonton, Canada), R. Zamanian (Palo Alto, United States of America)
| |
Clinical and investigational profiles of elevated pulmonary artery pressures in patients with stable chronic obstructive pulmonary diseases
M. Yousif (Shebin Elkom, Egypt), M. Agha (Shebin Elkom, Egypt), R. Habib (Shebin Elkom, Egypt), N. Elhelbawy (Shebin Elkom, Egypt), W. Abdou (Shebin Elkom, Egypt)
| |
Elevated pulmonary vascular resistance is associated with increased risk of death in IPF
A. Kapasi (Edmonton, Canada), K. Halloran (Edmonton, Canada), A. Hirji (Edmonton, Canada), D. Lien (Edmonton, Canada), J. Mooney (Palo Alto, United States of America), R. Raj (Palo Alto, United States of America), A. Sweatt (Palo Alto, United States of America), J. Weinkauf (Edmonton, Canada), R. Zamanian (Palo Alto, United States of America)
| |
Rest and exercise pulmonary arterial compliance in patients with pulmonary fibrosis
E. Panagiotidou (Thessaloniki, Greece), I. Stanopoulos (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), S. Akritidou (Thessaloniki, Greece), V. Bagalas (Thessaloniki, Greece), A. Boutou (Thessaloniki, Greece), G. Pitsiou (Thessaloniki, Greece)
| |
Body mass index predicts survival in patients with pulmonary hypertension in chronic lung disease
O. Nishiyama (Osakasayama, Japan), K. Yoshikawa (Osakasayama, Japan), S. Saeki (Osakasayama, Japan), R. Yamazaki (Osakasayama, Japan), H. Sano (Osakasayama, Japan), T. Iwanaga (Osakasayama, Japan), Y. Tohda (Osakasayama, Japan)
| |
Outcome of pulmonary hypertension associated with respiratory disease
L. Piccari (Barcelona, Spain), I. Blanco (Barcelona, Spain), M. López-Meseguer (Barcelona, Spain), R. Del Pozo (Huelva, Spain), X. Pomares (Sabadell, Spain), S. Santos (Barcelona, Spain), J. De Miguel (Madrid, Spain), G. Juan (Valencia, Spain), M. Rodríguez (Madrid, Spain), E. Sala (Palma de Mallorca, Spain), L. Jara (Sevilla, Spain), J. Domingo-Morera (Zaragoza, Spain), P. Escribano-Subías (Madrid, Spain), A. Martínez-Menaca (Santander, Spain), G. Pérez (Canarias, Spain), J. Barberà (Barcelona, Spain), D. Rodríguez (Barcelona, Spain)
| |
Novel evaluation of pulmonary hypertension with chronic lung disease by perfusion SPECT/CT
K. Atsumi (Tokyo, Japan), H. Hayashi (Tokyo, Japan), S. Nishima (Tokyo, Japan), T. Tanaka (Tokyo, Japan), T. Kashiwada (Tokyo, Japan), Y. Saito (Tokyo, Japan), M. Seike (Tokyo, Japan), A. Gemma (Tokyo, Japan), Y. Kubota (Tokyo, Japan), Y. Fukushima (Tokyo, Japan), H. Kimura (Tokyo, Japan)
| |
Psychological factors in patients with right heart failure associated with COPD
K. Rosales Castillo (Ciudad de México, Mexico), C. Pineda-Sánchez (Ciudad de México, Mexico), V. Peláez-Hernández (Ciudad de México, Mexico), L. Pachicano Romero (Ciudad de México, Mexico), A. Orea-Tejeda, (Ciudad de México, Mexico), G. Luna-Rodríguez (Ciudad de México, Mexico), L. Martínez- Bautista (Ciudad de México, Mexico), C. Zepeda-Domínguez (Ciudad de México, Mexico), . Ibarra-Fernández (Ciudad de México, Mexico), D. González-Islas (Ciudad de México, Mexico), R. Sánchez-Santillán, (Ciudad de México, Mexico), L. Hernández-Urquieta (Ciudad de México, Mexico), A. Flores-Vargas (Ciudad de México, Mexico), K. Balderas-Muñoz (Ciudad de México, Mexico), A. Jiménez-Valentín (Ciudad de México, Mexico), L. García-Flores (Ciudad de México, Mexico), M. Salgado-Fernández (Ciudad de México, Mexico), R. Dávila-Ramos (Ciudad de México, Mexico)
| |